Insiders, Venture

What are the top 10 corporate VCs in biopharma today? And what do they want to fund — or steer clear of?

Corporate money from Big Pharma is bleeding into private equity deals at a rapid clip, now representing a huge chunk of the total cash pie doled out to biotech ventures each year. Their motivations have moved beyond stocking research-starved pipelines, instead moving into private finance because the ideas they stumble on can influence longterm strategy.

Plus, well… they could use the returns.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 26,000+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 25,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Primer Washington 2018

RAPS Fundamentals 2018